NCT03823703 - Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Participants With Presumed Nonalcoholic Steatohepatitis (NASH) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 4, 2020

Primary Completion Date

April 5, 2021

Study Completion Date

April 5, 2021

Conditions

Nonalcoholic Steatohepatitis (NASH)

Interventions

DRUG

Miricorilant

Tablets taken orally

DRUG

Placebo

Placebo tablets

Trial Locations (15)

Site 232, East Syracuse

Site 234, Port Orange

Site 210, Sarasota

Site 228, Kansas City

Site 212, San Antonio

Site 213, Edinburg

Site 215, Edinburg

Site 211, Austin

Site 207, Chandler

Site 208, Glendale

Site 209, Tucson

Site 227, Los Angeles

Site 214, Panorama City

Site 233, Santa Ana

Site 226, Seattle